Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5641579 | 0.88 | TAAR1 (0.31) | TAAR1 | |
| SCHEMBL5642723 | 0.83 | — | — | |
| SCHEMBL6440848 | 0.82 | — | — | |
| SCHEMBL5644560 | 0.80 | — | — | |
| SCHEMBL5643967 | 0.78 | — | — | |
| SCHEMBL5642096 | 0.77 | ALDH1A1 (0.32) | — | |
| SCHEMBL5642522 | 0.76 | TAAR1 (0.47) | TAAR1 | |
| SCHEMBL5644676 | 0.73 | — | — | |
| SCHEMBL5643344 | 0.72 | — | — | |
| SCHEMBL5643706 | 0.72 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7250433-B2 | Tetrazole and oxadiazolone substituted β-amino acid derivatives | WARNER LAMBERT COMPANY LLC (US) | 2007-07-31 | — | — | US | claimed |
| EP-1603890-A1 | TETRAZOLE AND OXADIAZOLONE SUBSTITUTED &bgr;-AMINO ACID DERIVATIVES | Warner-Lambert Company LLC (US) | 2005-12-14 | — | — | EP | claimed |
| US-20050014804-A1 | Tetrazole and oxadiazolone substituted beta-amino acid derivatives | BARTA NANCY SUE (US) | 2005-01-20 | — | — | US | claimed |
| WO-2004078734-A1 | TETRAZOLE AND OXADIAZOLONE SUBSTITUTED β-AMINO ACID DERIVATIVES | WARNER-LAMBERT COMPANY LLC (US) | 2004-09-16 | — | — | WO | claimed |
| US-7250433-B2 | Tetrazole and oxadiazolone substituted β-amino acid derivatives | WARNER LAMBERT COMPANY LLC (US) | 2007-07-31 | — | — | US | disclosed |
| US-7250433-B2 | Tetrazole and oxadiazolone substituted β-amino acid derivatives | WARNER LAMBERT COMPANY LLC (US) | 2007-07-31 | — | — | US | disclosed |
| US-7250433-B2 | Tetrazole and oxadiazolone substituted β-amino acid derivatives | WARNER LAMBERT COMPANY LLC (US) | 2007-07-31 | — | — | US | disclosed |
| EP-1603890-A1 | TETRAZOLE AND OXADIAZOLONE SUBSTITUTED &bgr;-AMINO ACID DERIVATIVES | Warner-Lambert Company LLC (US) | 2005-12-14 | — | — | EP | disclosed |
| US-20050014804-A1 | Tetrazole and oxadiazolone substituted beta-amino acid derivatives | BARTA NANCY SUE (US) | 2005-01-20 | — | — | US | disclosed |
| WO-2004078734-A1 | TETRAZOLE AND OXADIAZOLONE SUBSTITUTED β-AMINO ACID DERIVATIVES | WARNER-LAMBERT COMPANY LLC (US) | 2004-09-16 | — | — | WO | disclosed |
| WO-2004078734-A1 | TETRAZOLE AND OXADIAZOLONE SUBSTITUTED β-AMINO ACID DERIVATIVES | WARNER-LAMBERT COMPANY LLC (US) | 2004-09-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050014804-A1 | Tetrazole and oxadiazolone substituted beta-amino acid derivatives | GLRA2, CACNG5, GLRB | TAAR1 414/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.